University of Michigan Rogel Cancer Center researchers are unraveling its nuances, advancing enabling technologies, advocating for patients and figuring out how to ethically integrate this technology into clinical care.

Experts at Michigan Medicine are focusing on helping people with chronic pain, which is defined as pain that lasts more than three months.

Through a collaboration with Stanford University, researchers have received an initial $1.1 million in funding from the NIH HEAL Initiative to expand data capabilities in search of solutions.

New study aims to understand and reduce persistent postoperative opioid use among older surgical patients

The award was presented this spring at the 2023 SIAM Conference on Applications of Dynamical Systems in Portland, OR.

A Michigan Medicine expert describes immunotherapy as “the future of cancer treatment” for those who qualify.

Research from experts at Michigan Medicine shows that significant language-based disparities exist in patients’ access to cancer care services, and it’s well before their first appointment with a doctor. 

Department of Anesthesiology runners hit the pavement this summer — from mile runs and 5k races to something a bit more extreme.

Cancer survivors who received treatment at the University of Michigan Health Rogel Cancer Center and infusion nurses demystify the experience by providing 10 helpful things to know ahead of time.

Early findings of two studies from the University of Michigan Rogel Cancer Center shed light on new ways to anticipate recurrence in HPV-positive head and neck cancer sooner. The papers, published in Cancer and Oral Oncology, offer clinical and technological perspectives on how to measure if recurrence is happening earlier than current blood tests allow, and provide a framework for a new, more sensitive blood test that could help in this monitoring.

A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a Michigan Medicine study finds.

Research from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.